

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan penelitian *literature review* pada 10 artikel ilmiah mengenai efektivitas dan keamanan penggunaan Empagliflozin pada pasien DM dengan komplikasi gagal jantung atau penyakit kardiovaskular dapat disimpulkan bahwa:

1. Empagliflozin memiliki efektivitas dalam memperbaiki kondisi penyakit kardiovaskular pada pasien DMT2 dengan menurunkan HbA1c, tekanan darah, kejadian rawat inap gagal jantung dan kematian akibat kardiovaskular, kejadian MACE, dan mempunyai efek renoprotektif.
2. Efek samping yang sering terjadi pada penggunaan empagliflozin adalah infeksi saluran kemih, infeksi genital, depleksi volume, dan ketoasidosis.

5.2 Saran

Perlu adanya tambahan literatur pendukung lainnya mengenai efektivitas dan keamanan Empagliflozin pada pasien DMT2 dengan komplikasi gagal jantung atau penyakit koridovaskular lainnya sehingga menjadi pertimbangan dalam pemberian terapi yang lebih baik.

DAFTAR PUSTAKA

- American Diabetes Association (ADA). 2019, *Standards of Medical Care in Diabetes 2019*. Diabetes Care, **42(1)**: 1-193
- American Diabetes Association (ADA). 2020, *Standards of Medical Care in Diabetes 2020*. Diabetes Care, **43(1)**: 1-212
- American Diabetes Association (ADA). 2021, *Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes 2021*. Diabetes Care, **44(1)**: 125-150.
- Bangsawan, M. Dan Purbianto. 2013, Faktor resiko yang mempercepat terjadinya komplikasi gagal jantung pada klien hipertensi, *Jurnal keperawatan*, **09(02)**: 145-150.
- Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., Broedl, U.C. 2014, Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial, *Diabetes endocrinology*, **2(1)**: 369-384.
- Bhanwra, S. and Ahluwalia, K. 2016, Empagliflozin: the latest SGLT2 inhibitor on the block, *International Journal of Basic & Clinical Pharmacology*, **5(2)**: 539-542.
- Birkeland, K.I., Jorgensen, M.E., Carstensen, B., Persson, F., Gulseth, H.L., Thuresson, M., Fenici, P., Nathanson, D., Nyström, T., Eriksson, J.W., Bodegård, J., Norhammar, A. 2017, Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis, *Diabetes endocrinology*, 1-9
- Butler, J., Zannad, F., Fitchett, D., Zinman, B. 2019, Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure, *Journal of American Heart Association*, 2-11.
- Candelario, N. and Wykretowicz, J. 2016, The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin, *Oxford medical case report*, **7(1)**: 144-146.

- Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S., Woerle, H.J., Broedl, U.C., Johansen, O.E. 2015, Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes, *Diabetes, Obesity and Metabolism*, **17(22)**: 1180–1193.
- Cho, Y.K., Lee, J., Kang Y. M., Yoo, J.H., Park, J.Y., Jung, C.H. 2019, Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. *PLoS ONE*, **14(8)**: 1-12.
- Cronin, P., Ryan, F., Coughlan, M. 2008, Undertaking a literature review: a step-by-step approach, *British Journal of Nursing*, **17(1)**: 38-43.
- Decroli, E. 2019, *Diabetes Mellitus Tipe 2*, Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas, Padang.
- Dipiro, J.T., Wells, B.G., Schwinghammer, T.L., Dipiro, C.V. 2015, *Pharmacotherapy Handbook (Ninth Edition)*, McGraw-Hill Companies.
- Edward, C. and Chao. 2014, SGLT-2 Inhibitors: A New Mechanism for Glycemic Control, *Clinical Diabetes*, **32(1)**: 4-11.
- Fatimah, R. 2015, Diabetes Mellitus Type 2, *J MAJORITY*, **4(5)**: 93-101.
- Filardi, P.P., Avorago, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A.P., Sesti, G., Ferrannini, E. 2017, Mechanisms linking empagliflozin to cardiovascular and renal protection, *International Journal of Cardiology*, **241**: 450-456.
- Fitchett, D., Zinman, B., Butler, J., Borne, P., George, J.T., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., Johansen, O.E., Woerle, H.J., Inzucchi, S.E. 2018, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEVR trial, *European Heart Journal*, **39**: 363-370.
- Fitchett, D., Zinman, B., Wanner, C., Lachin, J.M., Hantel, S., Salsali, A., Johansen, O.E., Woerle, H.J., Broedl, O.C., Inzucchi, S.E. 2015, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial, *European Heart Journal*, 1-9
- Frampton, J.E. 2018, *Empagliflozin: A Review in Type 2 Diabetes*, Springer International Publishing.

- Freeman, J.S. 2013, Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium glucose co-transporter 2 inhibitors, *Postgrad Med*, **125(3)**: 14-26.
- Geerlings, S., Fonseca, V., Diaz, D.C., List, J., Parikh, S. 2014, Genital and urinary tract infections in diabetes: Impact of pharmacologically induced glucosuria, *Diabetes Research and Clinical Practice*, **103**: 373-381.
- Giacco, F., Brownlee, M. 2010, Oxidative stress and diabetic complications, *Circ res*, **107(9)**: 1-28.
- Inamdar, A. 2016, Heart Failure: Diagnosis, Management and Utilization, *Journal of clinical medicine*, **05(62)**: 1-28.
- International Diabetes Federation. 2013, *IDF Diabetes Atlas*, 9th ed., International Diabetes Federation.
- International Diabetes Federation. 2017, *IDF Diabetes Atlas*, 8th ed., International Diabetes Federation.
- Inzucchi, S.E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, Schmoor, C., Ohneberg, K., Johansen, O.D., George, J.T., Hantel, S., Bluhmki, E., Lachin, J.M. 2017, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial, *Diabetes care*, 1-8.
- Jensen, J., Omar, M., Kistorp, C., Poulsen, M.K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F. 2020, Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial, *American Heart Journal*, **228**: 47-56.
- Kaku, K., Lee, J., Mattheus, M., Kaspers, S., George, J., Woerle, H.J. 2016, Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease, *Circ j*, 1-7.
- Kementerian kesehatan RI. 2017, Buku Panduan Penilaian Teknologi Kesehatan.
- Kementerian kesehatan RI. 2018, INFODATIN Pusat Data dan Informasi Kemeterian Kesehatan RI Diabetes Sedunia.

- Kurniawan, S.N. 2012, Patofisiologi biomolekular neuropati diabetes, *NEURONA*, **29(04)**: 1-10.
- McPhee, S.J., Ganong, W.F. 2010, *Patofisiologi penyakit: Pengantar menuju kedokteran klinis*, Jakarta: ECG.
- Monteiro, P., Bergenstal, R.M., Toural, E., Inzucchi, S.E., Zinman, B., Hantel, S., Kis, S.J., Kaspers, S., George, J.T., Fitchett, D. 2019, Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial, *Research paper*, 1-8
- Morris, D. 2017, The SGLT2 inhibitors – where are we now?, *Journal of Diabetes Nursing*, **21 (05)**: 162-165.
- Packer, M., Anker, S.D., Butler, J., Filippatos, G., Pocock, S.J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C. 2020, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, *The new england journal of medicine*, 1-12
- Patorno, E., Pawar, A., Franklin, J.M., Najafzadeh, M., Dérua, A., Brodovicz, K.G., Sambevski, S. 2019, Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care, *Circulation*, **139 (01)**: 2822–2830.
- Perkumpulan endokrinologi indonesia, 2019, *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*, PERKENI, Jakarta.
- PERKI, 2015, *Pedoman Tatalaksana Gagal Jantung*, PERKI, Jakarta.
- Pham, D., Rocha, N.D.A., McGuire, D.K., Neeland, I.J. 2016, Impact of empagliflozin in patients with diabetes and heart failure, *Trends in cardiovascular medicine*, 1-7.
- Saraswati, M.R. 2016. Bali Endocrinology Update (BEU XIII) Endocrinology and Beyond. Denpasar: PT. Percetakan Bali.
- Silalahi, T.D.A. 2012, Nilai Diagnosis N-Terminal Prohormone of Brain Natriuretic Peptide untuk mendeteksi Gagal Jantung Kronik Diastolik pada Pasien Hemodialisis Rutin, *Jurnal Jedokteran Meditek*, **18(46)**: 5-17.
- Staels, B. 2017, Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms, *The American Journal of Medicine*, **130(6)**: 30-39.

- Teli, M. 2017, Quality of Life Type 2 Diabetes Mellitus at Public Health Center Kupang City, *Jurnal Info Kesehatan*, **15(1)** : 119-134
- Thrasher, J. 2017, Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies, *The American Journal of Medicine*, 130(6):4-17.
- Toklu, H.Z. 2015, Promoting evidence-based practice in pharmacies, *Integrated Pharmacy Research and Practice*, **4(1)**: 127-131
- WHO. 2016, *Defenition and diagnosis of diabetes mellitus and intermediate hyperglykemia*, WHO Library Cataloguing in Publication Data.
- Yohanes, D.C. 2020, Penghambat Sodium-Glucose Cotransporter-2 (SGLT2), *Acta Pharm Indo*, **8(1)**: 26-35.
- Zhang, Y.J., Mda, Han, S.L., MDb, Sun, X.F., 2018, Efficacy and safety of empagliflozin for type 2 diabetes mellitus Meta-analysis of randomized controlled trials, *Medicine*, **97(43)**: 1-15.
- Zinman, B., Inzucchi, S.E., Wanner, C., Hehnke, U., George, J., Johansen, O.E., Fitchett, D. 2018, Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME, *diabetologia*, 1-6.
- Zinman, B., Wanner, C., Lachin J. M, et al. 2015, EMPA REG OUTCOME investogators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes, *N Engl J Med*, **373**: 2117-2118.